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Background:  The mechanism of action by which ranolazine (RAN) reduces stress-induced myocardial ischemia is not fully understood. 
We hypothesized that RAN relieves ischemia through the cardioprotective effects of adenosine (ADEN).
methods:  Non-flow limiting stenosis was created in the LAD artery in 17 open-chest dogs. We compared hemodynamic changes, global 
(peak LV dP/dt) and regional (radial strain) myocardial function, myocardial perfusion, and regional ADEN level in the absence and 
presence of intravenous RAN at rest and during dobutamine (DOB) stress.
results:  With stenosis, RAN significantly reduced the rate-pressure product, LAD pressure without changing pressure gradient, peak LV 
dP/dt without changing left atrial pressure, and radial strain. It had no effect on LAD blood flow. DOB produced the opposite effects, which 
were not altered with the addition of RAN. Blood flow improved and ADEN increased at rest and with DOB in the presence of RAN. Arterial 
blood volume also increased without change in myocardial blood volume, implying dilatation of intramyocardial vessels.
Conclusion:  RAN increased myocardial ADEN levels, which likely is cardioprotective during exercise-induced ischemia. The mechanism 
of increased ADEN levels induced by RAN is unknown but may be related to increased availability in association with resistance vessel 
dilatation. This is the first observation of this novel mechanism of action of RAN during intravenous administration.
